MENU

Organoids: A Revolutionary New Tool for Drug Screening

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director, Scientific Engagement, Crown Bioscience, Inc.
    Biography
      Rekha is a trained cancer biologist with a focus on preclinical cancer therapeutics, immune-oncology, cancer signaling, and tumor microenvironment. She earned her Ph.D. in Biochemistry from Central Drug Research Institute, India.
      She joined the University of Pittsburgh as a postdoctoral researcher and moved onto research faculty. She has extensively worked in stem cell biology and translational cancer research using patient's blood, tumor and bone marrow samples with a correlation of clinical data for the targeted biomarker identification with the drug treatment.
      She joined National Surgical Adjuvant Breast and Bowel project (NSABP), a clinical trial supportive group to develop strategies for preclinical evaluation of test agents to support NSABP's phase I/II clinical trials for colon and breast cancer. She also led the effort of organoids generation from the PDX tumor tissue to screen drug or drugs combination as personalized medicine. Rekha represented NSABP as a translational research committee member on B-50 Katherine-B027938 Roche study.
      Rekha role at CrownBio is to direct scientific engagement with pharmaceutical company, academic scientists, and clients. She helps in decision making with goal of high scientific input in study design and model execution. Exchange scientific information for existing and new opportunities between BD and the scientific team, generate protocols, study designs and proposals to define projects/ studies.

    Abstract

    “The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo genetic drift over time due to adapting to in vitro growth, thus showing limited relevance to the human disease. Interpatient tumor heterogeneity is also a major hurdle with standard in vitro models failing to recapitulate this variability. Patient-derived xenografts are the gold standard preclinical models for their proven translatability to the human disease but can be costly and time consuming to generate and maintain. The Hubrecht Organoid Technology (HUB) has pioneered the development of tumor organoids, a revolutionary patient-derived 3D in vitro system that recapitulates the genomic, morphological, and pathophysiological characteristics of their parental tumor. HUB organoids provide highly clinically relevant 3D in vitro models for oncology drug development. To overcome the limitation imposed by sourcing patient material for organoid preclinical development PDX can be used as a source of human tumor tissue leading to a patient-relevant matched in vitro/in vivo platform for oncology drug screening.”

    Learning bullets:
    1. Find out why HUB organoids are considered best in class systems
    2. Understand how organoids are revolutionizing oncology drug development
    3. Learn about how patient-derived xenografts (PDX) can be leveraged to develop the largest organoid library for oncology drug discovery


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources